Key Highlights
- Ivana Magovčević-Liebisch brings over 25 years of biopharma experience to Quanterix.
- Founder and CEO of Vigil Neuroscience, leading Alzheimer’s therapy development.
- Quanterix’s Simoa® technology at the forefront of blood-based neuro biomarkers.
Source: Business Wire
Notable Quotes
- “Ivana’s business acumen and leadership experience will be invaluable as Quanterix expands its existing biomarker partnerships with pharma and biotech.” — Masoud Toloue, CEO at Quanterix
- “Joining Quanterix’s Board of Directors presents an exciting opportunity to contribute to continued innovation and advancement in the industry.” — Ivana Magovčević-Liebisch, Ph.D., J.D., President and CEO at Vigil Neuroscience
SoHC's Take
The addition of Dr. Ivana Magovčević-Liebisch to Quanterix’s Board of Directors is a strategic move that aligns with the company’s mission to drive advancements in biomarker detection and diagnostics. Her extensive background in biopharmaceutical R&D, business development, and commercialization, combined with her leadership in neurology therapies, strengthens Quanterix’s position in expanding its biomarker partnerships and clinical diagnostics capabilities. Her expertise will be particularly valuable as Quanterix continues to innovate in a competitive and fast-evolving market.
